EGFR and lung cancer: The case highlights the importance of rebiopsy and molecular retesting after the progression of lung cancer and supports the idea that the combination of immune checkpoint blockade and chemotherapy may be an attractive option for patients with <i>EGFR</i> ex20 mutations associated with LUSC-LUAD transformation.